Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
In recent years, there have been significant changes in the recombinant vaccine market along with improvements in vaccine technology, greater demand for preventive medicine and increased global interest in vaccine development and distribution. Recombinant vaccines derived from genetically engineered microorganisms expressing specific antigens have gained popularity due to their safety, efficacy and scalability.
One area of interest is increasing attention on vaccine research for emerging infectious diseases. The COVID-19 pandemic has emphasized the urgency of the need for vaccines resulting into rapid production and introduction of recombinant vaccines against SARS-CoV-2 virus. This context has driven ongoing ability to innovate and adjust the sales of recombinant vaccination with more stabs at upcoming new pathogens as well as likely outbreaks.
Advancements in technology have therefore played a critical role in shaping this market segment which deals with recombinant vaccines. For instance, through utilization of latest biotechnological tools such as CRISPR-Cas9 gene-editing technique and synthetic biology, it has allowed for faster product development leading to better immunogenicity-based vaccines. These technology trends also improve not only efficiency in vaccine manufacture but also enable next-generation recombinant vaccines that are effective against different strains to be developed.
Collaboration and cooperation across the pharmaceuticals and biotechnology industries were key features within theoretical constructs influencing the world’s third largest therapeutic class, recombinant vaccines business today. Strategic alliances between different companies academic and research institutions are responsible collaborative approaches towards developing vaccinations. These partnerships help combine resources, expertise and infrastructure for quicker researches clarifying how best these products may be commercialized within a very short period thus reducing time-to-market for new drugs produced by combining genetic material from microorganisms. This trend will continue thereby accelerating vaccine innovation.
The emphasis on preventive healthcare coupled with an increasing awareness about vaccination value explains why there has been an uptick in uptake rates when it comes to usage of recombined vaccines. Vaccination programs are being pushed by governments, public health entities companies among other private sector enterprises to help prevent infectious diseases spread and relieve the healthcare system of such stresses. The focus on prevention along with heightened public awareness of vaccine effectiveness and safety are fueling demand for recombinant vaccines as a preferred means of disease prevention.
Another trend in this market is moving towards the development of non-communicable disease vaccines. Studies have shown that recombinant vaccines can be useful in treating cancers, allergic disorders and autoimmune illnesses. This expansion away from infections only shows how flexible these platforms are in making recombinant vaccines capable of addressing various health issues at hand.
The whole world is calling for improved access and affordability of vaccines as one of the vital trends in the recombinant vaccine market. Initiatives like COVAX aim at ensuring that everyone has equal opportunities to get vaccinated especially those from low-income and middle-income countries. This global commitment not only addresses public health concerns but also builds stronger sustainable and inclusive markets for recombinant vaccines.
Regulatory drivers as well as advancements are important factors influencing the development of this market dealing with recombined vaccinations. To date, regulatory agencies worldwide have been reformulating their frameworks to accommodate peculiarities associated with recombined vaccination products .Such reforms include fast-tracking approval processes, increased collaboration between regulators and manufacturers, designing clear-cut regulatory pathways leading into faster marketing environment for these products than anticipated by many people everywhere thus leading to a situation whereby recombinants enter commerce swifter than we expect them to do so.
Recombinant Vaccines Market Highlights:
Global Recombinant Vaccines Market Overview
Recombinant Vaccines Market Size was valued at USD 0.29 Billion in 2023. The Global Recombinant Vaccines industry is projected to grow from USD 0.36 Billion in 2024 to USD 1.62 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.24% during the forecast period (2024 - 2032).
Vaccines that are produced using the recombinant DNA technology or genetic engineering are called recombinant vaccines.
The recombinant vector vaccine strategy enables triggering of T- cells and antigens, thus generating a strong cell-mediated immune response in the body against that particular immunogen. The market is majorly driven by increasing technical advanced devices, increasing number of regulatory approvals, the high prevalence of infectious diseases, and growing penetration of key market players.
Furthermore, raising awareness of healthcare, favorable reimbursement policies, increasing innovations in research and development of drugs, and vaccines, as well as rising average income of individuals, are fueling the recombinant vaccines market growth. However, factors such as high cost of vaccines, risks associated with live attenuated vaccines, as well as sore throat irritability after vaccine administration and stringent regulatory policies are likely to hamper the growth of the market. Lack of proper health care infrastructure, as well as awareness regarding pathogen-related diseases in middle-income countries, are a major challenge to the market growth.
Recombinant Vaccines Market Key Players
- Abiomed
- Emergent Bio Solutions, Inc.
- GlaxoSmithKline
- Johnson & Johnson
- Sanofi Pasteur SA
- Serum Institute of India Pvt. Ltd
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo
- Pfizer, Inc.
Recombinant Vaccines Market Segmentation
The recombinant vaccines market is segmented on the basis of product type, diseases, and end-user. According to the product, the market is segmented into subunit recombinant vaccines, attenuated recombinant vaccines, and vector recombinant vaccines,
Considering the disease type, the market is segmented into pneumococcal disease, cancer, hepatitis B, influenza, DPT, and others.
On account of the end-user, the market is segmented into hospitals & clinics, pediatrics, adults, veterinary, and others. Veterinary is further segmented to poultry and livestock.
Based on the region the market is segmented into Americas, Europe, Asia Pacific, and the Middle East and Africa. The American region is segmented into North America and South America. Similarly, Europe is segmented into Western Europe and Eastern Europe.
Recombinant Vaccines Market Regional Analysis
Americas is the global leader in recombinant vaccines market owing to increasing advances in molecular biology and genetic engineering techniques as well as increasing prevalence of infectious diseases. Additionally, factors such as increasing government initiatives and funding for research, development of advanced medical treatment options, and rising demand for technologically advanced treatment are likely to enhance the growth of market in the American region.
For instance, According to stats presented in the Centers for Disease Control and Prevention report in the year 2017, around 49.9% of the children between the ages of 6 months to 17 years in the U.S. received an influenza vaccine. Due to the alarming rate of diseases associated with opportunistic pathogen developed countries are introducing compulsory immunization program. Raising global burden of cancer has also led a lot of key players to invest their time and money to come up with solutions to curb this problem. For instance, The vaccine therapy with or without trastuzumab as well as GM-CSF vaccine for the treatment of breast cancer is in phases II clinical trial. Green signal from regulatory bodies for these vaccines will further boost up the recombinant vaccines market growth
Europe is the second largest market and holds a healthy share in the market due to major driving factors like availability of advanced treatment facilities, increasing healthcare expenditure along with an alarming rate of cancer and infectious diseases. Furthermore, Lots of established key players in this region export their products to the developing nation. For instance, the European Commission stated that the R&D spending by the pharmaceuticals and biotechnology sectors grew by 8.7% in 2014. This investment in R&D along with the ongoing legislative reforms is expected to have a positive impact on the recombinant vaccines market.
Asia Pacific is expected to be the fastest growing market owing to the faster adaptation of healthcare technology, increasing inpatient pool due to cancer and infectious diseases, government initiatives to increase the healthcare quality, favorable insurance, and reimbursement policies. Key players have set up their regional headquarters and manufacturing plants in Singapore, China, Japan, Korea, and Australia thus, boosting the growth of market. Government is also taking several initiatives to spread awareness in the low-income areas. National Immunization Program In India has helped people below the poverty line get immunized against polio as well as DPT. However, on the other hand, factor such as lack of skilled healthcare professionals may slow down the recombinant vaccines market growth during the forecast period.
The Middle East and Africa is expected to show the least growth in the market due to some major factors such as lack of awareness, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates is the largest market share owing to the development of healthcare industry and rising availability of specialty care centers. However, this area has the possibility to grow during the forecast period as due to increasing outbreak of new opportunistic pathogen associated diseases like Ebola, Zika Virus, and Hepatitis B government along with some key planners have set up their R&D centers in this region.
Intended Audience
- Pharmaceutical Manufacturers and Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Market Segmentation
Recombinant Vaccines Market, by Type
- Subunit recombinant vaccines
- Attenuated recombinant vaccines
- Vector recombinant vaccines
Recombinant Vaccines Market, by Disease
- Pneumococcal Disease
- Cancer
- Hepatitis B
- Influenza
- DPT
- Others
Recombinant Vaccines Market, by End-User
- Hospitals & Clinics
- Pediatrics
- Adults
- Veterinary
- Poultry
- Livestock
- Others
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
